DRNA News and Press, Dicerna Pharmaceuticals Inc. From 11/09/21

Image source: The Motley Fool. Dicerna Pharmaceuticals, Inc (NASDAQ: DRNA) Q3 2021 Earnings Call Nov 9, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Dicerna Pharmaceuticals, Inc (DRNA) Q3 2021 Earnings Call Trans...

Dicerna Pharmaceuticals, Inc. (DRNA) Q3 2021 Earnings Conference Call November 9, 2021 8:30 AM ET Company Participants Kristen Sheppard - Senior Vice President of Investor Relations Doug Fambrough - Chief Executive Officer Doug Pagan - Chief Financial Officer Shreeram Aradhye - Chief Medical ...

Dicerna Pharmaceuticals (NASDAQ:DRNA): Q3 GAAP EPS of -$0.22 beats by $0.28. Revenue of $62.95M (+28.8% Y/Y) beats by $19.17M. Press Release For further details see: Dicerna Pharmaceuticals EPS beats by $0.28, beats on revenue

– Reported Positive Top-Line Data From Pivotal PHYOX™2 Clinical Trial of Nedosiran Investigational GalXC™ RNAi Therapy for Treatment of Primary Hyperoxaluria (PH) – – Initiated Phase 1 Clinical Trial of DCR-AUD for the Treatment of Alcohol Us...

Dicerna Pharmaceuticals (NASDAQ:DRNA) is scheduled to announce Q3 earnings results on Tuesday, November 9th, before market open. The consensus EPS Estimate is -$0.43 (-48.3% Y/Y) and the consensus Revenue Estimate is $43.78M (-10.5% Y/Y). Over the last 3 months, EPS estimates have seen 2 upwa...

ADT,AGEN,AGTC,ALLT,APRN,AUD,OTCPK:BAYZF,BHVN,BNTX,BSY,CAH,CANO,CCO,CEVA,CNCE,CORR,DCTH,DHI,DRNA,EBIX,ECOM,EGRX,EPZM,EXK,FOLD,GILT,GLNG,GOL,HAE,HAIN,HGV,HUYA,IGT,IIVI,INSW,ISEE,ITCI,KNDI,KPLT,MIDD,MLCO,MNTV,MRNS,MRSN,MSGE,OTCPK:NSANY,NSPR,NUWE,OCGN,OESX,OSG,OWL,PLTR,PRPL,PRTY,QTNT,SATS,SEAS,SE...

– Nedosiran Achieved Primary Endpoint Demonstrating Statistically Significant Sustained Reduction in Urinary Oxalate Excretion and Showed Robust Efficacy in PH1 – – Real-World Healthcare Utilization Data Showed Delayed Diagnosis in More Than 50% of Patient...

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2021 financial results bef...

– Study Met Primary Safety Endpoint; Nedosiran Shown to be Generally Safe and Well Tolerated in Patients With PH3 – – Although Trial Did Not Meet Prespecified Secondary Efficacy Endpoint, Data Showed Encouraging Trends in Urinary Oxalate Reduction With Ned...

– Data From PHYOX™2 Pivotal Trial of Nedosiran for Treatment of Primary Hyperoxaluria (PH) Accepted as Late-Breaker Poster Presentation – – Company on Track to Submit Nedosiran New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA...